Arcellx, Inc.
ACLX
Peringkat dalam Saham
#2745
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to... Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
Harga Saham
$115.07
Terakhir disinkronkan: 2026-05-15
Kapitalisasi Pasar
$6.73B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
38.04%
Negara
US
Perdagangan Arcellx, Inc. (ACLX)
Kategori
Healthcare
Riwayat harga saham Arcellx, Inc. (ACLX)
Harga penutupan tertinggi: $115.07 pada 2026-05-01
Harga penutupan terendah: $17.58 pada 2022-02-01
Harga penutupan terendah: $17.58 pada 2022-02-01
Riwayat harga saham Arcellx, Inc. dari 2022 hingga 2026
Performa harga saham tahunan
| Tahun | Performa |
|---|---|
| 2026 (TTM) | 30.35% |
| 2025 | -17.00% |
| 2024 | 52.40% |
| 2023 | 93.55% |
| 2022 | 0.00% |
Harga saham perusahaan atau pesaing serupa
| Perusahaan | Harga saham | Perubahan 1th% | Negara |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $757.97 | 7.73% |
CH
|
